Title |
Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
|
---|---|
Published in |
Orphanet Journal of Rare Diseases, October 2011
|
DOI | 10.1186/1750-1172-6-69 |
Pubmed ID | |
Authors |
Bouwien E Smid, Saskia M Rombach, Johannes MFG Aerts, Symen Kuiper, Mina Mirzaian, Hermen S Overkleeft, Ben JHM Poorthuis, Carla EM Hollak, Johanna EM Groener, Gabor E Linthorst |
Abstract |
Enzyme replacement therapy is currently the only approved therapy for Fabry disease. From June 2009 on, viral contamination of Genzyme's production facility resulted in a worldwide shortage of agalsidase beta leading to involuntary dose reductions (approved dose 1 mg/kg/eow, reduced dose 0.5 mg/kg/m), or switch to agalsidase alpha (administered dose 0.2 mg/kg/eow). An assessment report from the European Medicines Agency (EMA) raised serious concerns about an increase in adverse events at lower dosages of agalsidase beta. We determined the influence of the shortage on clinical event incidence and the most sensitive biochemical marker (lysoGb3) in Dutch Fabry patients. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 76 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 11 | 14% |
Student > Ph. D. Student | 10 | 13% |
Student > Bachelor | 9 | 12% |
Student > Master | 8 | 11% |
Other | 4 | 5% |
Other | 8 | 11% |
Unknown | 26 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 23 | 30% |
Biochemistry, Genetics and Molecular Biology | 6 | 8% |
Agricultural and Biological Sciences | 5 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Social Sciences | 3 | 4% |
Other | 8 | 11% |
Unknown | 27 | 36% |